ITEMS IN AFP WITH KEYWORD:
Jan 1, 2008 Issue
Choosing First-Line Therapy for Management of Type 2 Diabetes [AFP Journal Club]
Which controls type 2 diabetes best at five years: rosiglitazone, metformin, or glyburide? Metformin should be the first-line drug for managing type 2 diabetes. Insulin and sulfonylureas should be second line, and glitazones should be reserved for third line.
Oct 1, 2007 Issue
Does Pioglitazone Benefit Patients With Type 2 Diabetes? [Cochrane for Clinicians]
Pioglitazone produces a reduction in A1C levels similar to that produced by other drugs. One trial found that although pioglitazone, used as an adjunct to other antihyperglycemic medications, may lead to a statistically significant reduction in morbidity and mortality in patients with established ma...
Sitagliptin may be useful as second-line or third-line therapy in patients with a mildly elevated A1C level (less than 9 percent) who do not reach their A1C goal with first-line therapy (metformin). Sitagliptin will decrease postprandial blood glucose and mildly lower fasting blood glucose for a total A1C reduction around 0.8 percent.
Although type 1 diabetes historically has been more common in patients eight to 19 years of age, type 2 diabetes is emerging as an important disease in this group. Type 2 diabetes accounts for 8 to 45 percent of new childhood diabetes. This article is an update from the National Diabetes Education P...
Aug 1, 2007 Issue
Alpha-glucosidase Inhibitors May Reduce the Risk of Type 2 Diabetes [Cochrane for Clinicians]
The literature shows that acarbose can reduce the risk of type 2 diabetes in patients with impaired glucose tolerance or impaired fasting glucose. However, it is unclear whether the drug stops or delays the development of the disease or masks the diagnosis. There is no evidence that acarbose use red...
Home monitoring of blood glucose and blood pressure levels can provide patients and physicians with valuable information in the management of diabetes mellitus and hypertension. Home monitoring allows patients to play an active role in their care and may improve treatment adherence and clinical outc...
The American Diabetes Association currently recommends an A1C goal of less than 7 percent. However, many patients are unable to achieve this goal by using oral drug combinations or diet and exercise, leaving insulin as the only treatment option. In most cases, insulin is initiated later in therapy b...
Inhaled insulin provides an alternative route of administration for rapid-acting insulin but offers no other benefit over available insulin therapy. It may reduce, but not eliminate, the need for self-injection in patients with type 1 diabetes. In patients with type 2 diabetes, the risk of hypoglyce...
Feb 1, 2007 Issue
The Role of Exercise in Patients with Type 2 Diabetes [Cochrane for Clinicians]
Regular exercise reduces A1C levels, adiposity, and triglyceride levels. However, no research has definitively proved a benefit of exercise on patient-oriented outcomes such as diabetes-related morbidity and mortality.
Jan 15, 2007 Issue
CDC Releases Data on Visual Impairment in Patients with Diabetes [Practice Guidelines]
The Centers for Disease Control and Prevention (CDC) has released data on visual impairment in patients with diabetes. Patients with diabetes are more likely to be visually impaired than those who do not have the disease.